REFERENCES

1. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.

2. Ulaner GA, Hyman DM, Ross DS, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. J Nucl Med 2016;57:1523-8.

3. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics 2019;20:273-86.

4. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 2020;323:844-53.

5. Hingorani AD, Kuan V, Finan C, et al. Improving the odds of drug development success through human genomics: modelling study. Sci Rep 2019;9:18911.

6. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 2015;91:3-6.

7. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.

8. Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science 2019;364:952-5.

9. Mullenders J, de Jongh E, Brousali A, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci U S A 2019;116:4567-74.

10. Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 2018;172:373-386.e10.

11. Tiriac H, Belleau P, Engle DD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov 2018;8:1112-29.

12. HCMI. Available from: https://www.atcc.org/Products/Cells%20and%20Microorganisms/HCMI.aspx [Last accessed on 7 Jul 2021].

13. Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 2020;20:174-86.

14. Biffi G, Oni TE, Spielman B, et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov 2019;9:282-301.

15. Miyabayashi K, Baker LA, Deschênes A, et al. Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. Cancer Discov 2020;10:1566-89.

16. Capecchi MR. Altering the genome by homologous recombination. Science 1989;244:1288-92.

17. Sandy P, Ventura A, Jacks T. Mammalian RNAi: a practical guide. Biotechniques 2005;39:215-24.

18. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2005;102:13212-7.

19. Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun 2018;9:1911.

20. Loew R, Heinz N, Hampf M, Bujard H, Gossen M. Improved Tet-responsive promoters with minimized background expression. BMC Biotechnol 2010;10:81.

21. Koga S, Oshima Y, Honkura N, et al. In vivo subcellular imaging of tumors in mouse models using a fluorophore-conjugated anti-carcinoembryonic antigen antibody in two-photon excitation microscopy. Cancer Sci 2014;105:1299-306.

22. Rice BW, Contag CH. The importance of being red. Nat Biotechnol 2009;27:624-5.

23. Li R, Attari A, Prytyskach M, Garlin MA, Weissleder R, Miller MA. Single-cell intravital microscopy of trastuzumab quantifies heterogeneous in vivo kinetics. Cytometry A 2020;97:528-39.

24. Voskuil FJ, de Jongh SJ, Hooghiemstra WTR, et al. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study. Theranostics 2020;10:3994-4005.

25. Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-Lavigne M. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 2014;159:896-910.

26. Weber J, Beard PC, Bohndiek SE. Contrast agents for molecular photoacoustic imaging. Nat Methods 2016;13:639-50.

27. Zhang C, Zhang Y, Hong K, Zhu S, Wan J. Photoacoustic and fluorescence imaging of cutaneous squamous cell carcinoma in living subjects using a probe targeting integrin α_vβ₆. Sci Rep 2017;7:42442.

28. Yoon JK, Park BN, Ryu EK, An YS, Lee SJ. Current perspectives on ⁸⁹Zr-PET imaging. Int J Mol Sci 2020;21:E4309.

29. Wu AM. Engineered antibodies for molecular imaging of cancer. Methods 2014;65:139-47.

30. Carter KP, Deblonde GJ, Lohrey TD, et al. Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals. Commun Chem 2020:3.

31. Lyons SK, Patrick PS, Brindle KM. Imaging mouse cancer models in vivo using reporter transgenes. Cold Spring Harb Protoc 2013;2013:685-99.

32. Yao Z, Zhang BS, Prescher JA. Advances in bioluminescence imaging: new probes from old recipes. Curr Opin Chem Biol 2018;45:148-56.

33. Vandergaast R, Khongwichit S, Jiang H, et al. Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging. Cancer Gene Ther 2020;27:179-88.